Pivotal study to form basis for upcoming biologic license application to the U.S. FDA DEERFIELD, Ill., JANUARY 8, 2013 - Baxter International Inc. (NYSE:BAX) today announced pivotal Phase III study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback